Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 105

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 7
Chunk 105
---
, 2024, the Company
entered into a Securities Purchase Agreement (“ Securities Purchase Agreement”) with JAK, pursuant to which, amongst other
things: (i) the Company agreed to sell, at an initial closing (and such initial closing, the “ Initial Closing”), (a) a senior
convertible note (the “ Initial Note”) in the aggregate original principal amount not exceeding $1,100,000, convertible into
Class A Ordinary Shares pursuant to its terms, (b) a warrant to purchase 1,325,301 Class A Ordinary Shares (such warrant, the “ Series
A Warrant”), and (c) a warrant to purchase 180,722 Class A Ordinary Shares (the “ Series B Warrant”); and (ii) the Company
may require JAK (or JAK may require the Company, as applicable) to participate in the sale of (a) one or more additional convertible notes
(which aggregate original principal amount for all additional convertible notes shall not exceed $9,500,000) (the “ Additional Notes”)
and (b) related Warrants. A copy of the Securities Purchase Agreement is filed as Exhibit 4.25 to this Report.

Additionally, in connection
with the Securities Purchase Agreement, the Company entered into amendment and exchange agreements with JAK, pursuant to which the Company
exchanged the Existing Notes by issuing, among other things, (i) senior convertible notes in the aggregate principal amount of $2,700,000
(the “ Exchange Notes”, and, together with the Initial Note and the Additional Notes, the “ Notes”) and (b) a series
of warrants to initially acquire up to a certain number of Ordinary Shares to JAK. The Exchange Notes are in substantially similar form
to the Initial Notes

During the year ended December
31, 2024, a total of $5,800,000 convertible notes were issued to JAK. JAK had converted $2,650,000 into Class A Ordinary Shares. The outstanding
convertible note as of December 31, 2024 was $3,150,000.

As of December 31, 2024, the warrants issued pursuant to the convertible
notes amount to 6,174,690 Series A warrant, 180,722 warrant B and 3,253,012 warrant C which entitles the holder to exercise its rights
to purchase Class A ordinary shares in the Company at an exercise price of $0.913, $0.001 and